ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.693,37
0,04%
S&P 500
5.304,72
0,70%
Dow Jones
39.069,59
0,01%
Euro vs US Dollar
1,08535
0,38%
Bitcoin
68.643,87
1,06%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. uniQure NV (QURE)

  7. uniQure NV (QURE) News

QURE

uniQure NV (QURE)

uniQure NV
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:QURE
DatumZeitQuelleÜberschriftSymbolFirma
07/05/202414h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
07/05/202413h57Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QUREuniQure NV
07/05/202413h05GlobeNewswire Inc.uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
05/03/202423h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
05/03/202423h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
05/03/202422h58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
05/03/202422h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
28/02/202422h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
28/02/202414h29Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:QUREuniQure NV
28/02/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
28/02/202413h05GlobeNewswire Inc.uniQure Announces 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
26/02/202422h46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:QUREuniQure NV
26/02/202422h25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:QUREuniQure NV
13/02/202422h33Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:QUREuniQure NV
19/12/202313h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
19/12/202313h05GlobeNewswire Inc.uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s DiseaseNASDAQ:QUREuniQure NV
12/12/202301h30PR Newswire (US)CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia BNASDAQ:QUREuniQure NV
08/12/202313h05GlobeNewswire Inc.uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:QUREuniQure NV
29/11/202313h05GlobeNewswire Inc.uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry DiseaseNASDAQ:QUREuniQure NV
17/11/202312h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
07/11/202313h52Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QUREuniQure NV
07/11/202313h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
07/11/202313h05GlobeNewswire Inc.uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
27/10/202316h00PR Newswire (US)CSL and uniQure Win 2023 Prix Galien USA AwardNASDAQ:QUREuniQure NV
26/10/202320h38PR Newswire (Canada)Santé Canada autorise HEMGENIX® de CSL (étranacogène dézaparvovec) comme première thérapie génique pour l'hémophilie BNASDAQ:QUREuniQure NV
26/10/202320h14PR Newswire (Canada)Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia BNASDAQ:QUREuniQure NV
24/10/202313h05GlobeNewswire Inc.uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual MeetingNASDAQ:QUREuniQure NV
06/10/202312h33Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:QUREuniQure NV
06/10/202312h32Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:QUREuniQure NV
05/10/202322h32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
 Showing the most relevant articles for your search:NASDAQ:QURE

Kürzlich von Ihnen besucht

NASDAQ
MSFT
Microsoft
TG
ALV
Allianz
USOTC
BASFY
BASF (QX)
COIN
BTCUSD
Bitcoin
NYSE
NKE
Nike
FX
EURUSD
Euro vs US Dollar
TG
RHM
Rheinmetall
NYSE
XOM
Exxon Mobil
NYSE
DIS
Walt Disney
TG
DTE
Deutsche Telekom
USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
MRK
Merck
CCOM
US30
US 30
NASDAQ
GOOGL
Alphabet
TG
MBG
MercedesBenz
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten